TY - JOUR
T1 - Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome
AU - Newton, Julia L.
AU - Frith, James
AU - Powell, Danielle
AU - Hackett, Kate
AU - Wilton, Katharine
AU - Bowman, Simon
AU - Price, Elizabeth
AU - Pease, Colin
AU - Andrews, Jacqueline
AU - Emery, Paul
AU - Hunter, John
AU - Gupta, Monica
AU - Vadivelu, Saravanan
AU - Giles, Ian
AU - Isenberg, David
AU - Lanyon, Peter
AU - Jones, Adrian
AU - Regan, Marian
AU - Cooper, Annie
AU - Moots, Robert
AU - Sutcliffe, Nurhan
AU - Bombardieri, Michele
AU - Pitzalis, Costantino
AU - McLaren, John
AU - Young-Min, Steven
AU - Dasgupta, Bhaskar
AU - Ths, Bridget Griffi
AU - Lendrem, Dennis
AU - Mitchell, Sheryl
AU - Ng, Wan Fai
PY - 2012/12
Y1 - 2012/12
N2 - Objectives: To determine the prevalence of autonomic dysfunction (dysautonomia) among patients with primary Sjögren's syndrome (PSS) and the relationships between dysautonomia and other clinical features of PSS. Methods: Multicentre, prospective, cross-sectional study of a UK cohort of 317 patients with clinically well-characterised PSS. Symptoms of autonomic dysfunction were assessed using a validated instrument, the Composite Autonomic Symptom Scale (COMPASS). The data were compared with an age- and sex-matched cohort of 317 community controls. The relationships between symptoms of dysautonomia and various clinical features of PSS were analysed using regression analysis. Results: COMPASS scores were significantly higher in patients with PSS than in age- and sex-matched community controls (median (IQR) 35.5 (20.9-46.0) vs. 14.8 (4.4-30.2), p<0.0001). Nearly 55% of patients (vs 20% of community controls, p<0.0001) had a COMPASS score >32.5, a cut-off value indicative of autonomic dysfunction. Furthermore, the COMPASS total score correlated independently with EULAR Sjögren's Syndrome Patient Reported Index (a composite measure of the overall burden of symptoms experienced by patients with PSS) (β=0.38, p<0.001) and disease activity measured using the EULAR Sjögren's Syndrome Disease Activity Index (β=0.13, p<0.009). Conclusions: Autonomic symptoms are common among patients with PSS and may contribute to the overall burden of symptoms and link with systemic disease activity.
AB - Objectives: To determine the prevalence of autonomic dysfunction (dysautonomia) among patients with primary Sjögren's syndrome (PSS) and the relationships between dysautonomia and other clinical features of PSS. Methods: Multicentre, prospective, cross-sectional study of a UK cohort of 317 patients with clinically well-characterised PSS. Symptoms of autonomic dysfunction were assessed using a validated instrument, the Composite Autonomic Symptom Scale (COMPASS). The data were compared with an age- and sex-matched cohort of 317 community controls. The relationships between symptoms of dysautonomia and various clinical features of PSS were analysed using regression analysis. Results: COMPASS scores were significantly higher in patients with PSS than in age- and sex-matched community controls (median (IQR) 35.5 (20.9-46.0) vs. 14.8 (4.4-30.2), p<0.0001). Nearly 55% of patients (vs 20% of community controls, p<0.0001) had a COMPASS score >32.5, a cut-off value indicative of autonomic dysfunction. Furthermore, the COMPASS total score correlated independently with EULAR Sjögren's Syndrome Patient Reported Index (a composite measure of the overall burden of symptoms experienced by patients with PSS) (β=0.38, p<0.001) and disease activity measured using the EULAR Sjögren's Syndrome Disease Activity Index (β=0.13, p<0.009). Conclusions: Autonomic symptoms are common among patients with PSS and may contribute to the overall burden of symptoms and link with systemic disease activity.
UR - https://www.scopus.com/pages/publications/84868359542
U2 - 10.1136/annrheumdis-2011-201009
DO - 10.1136/annrheumdis-2011-201009
M3 - Article
C2 - 22562982
AN - SCOPUS:84868359542
SN - 0003-4967
VL - 71
SP - 1973
EP - 1979
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 12
ER -